1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1640
  5. Art Unit 1641
  6. Examiner Haddad

Examiner Haddad Maher M

1641-HADDAD-MAHER-M

Employment Information

Art Unit:1641 — Drug, bio-affecting and body treating compositions
Group:1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology
Classes: 424 — Drug, bio-affecting and body treating compositions
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
435 — Chemistry: molecular biology and microbiology
514 — Drug, bio-affecting and body treating compositions
436 — Chemistry: analytical and immunological testing
Phone:(571) 272-0845
Email:maher.haddad@uspto.gov
Location:VA 22314
Title:Pat Examnr (Cbt-Biolgy)
Service:24 years
Grade:GS-15

Grant Rate and Difficulty Ranking

81
3-Year Grant rate: 50% over 429 cases
Difficulty: Very Hard
Difficulty Percentile: 81st

With Examiner Haddad, you have a 50% chance of getting an issued patent by 3 years after the first office action. Examiner Haddad is a very hard examiner and in the 81st percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Haddad, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1641

Examiner Haddad's grant rate is lower than that of Art Unit 1641 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Haddad 1.5
Art Unit 1641 1.8

Interview Benefit

Grant Rate without Interview

Examiner Haddad has granted 170 of 365 cases without any applicant-requested interviews for a grant rate of 47%.

Grant Rate with Interview

Examiner Haddad has granted 46 of 64 cases with at least one applicant-requested interview for a grant rate of 72%.

Interview Benefit

With Examiner Haddad, conducting an interview increases your chance of getting a patent granted by 53%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18514624 Compositions, Methods And/or Kits Comprising A Recombinant Human Cd38-Extracellular Domain Rejection information available with a Premium Stats subscription. See our pricing. Abandoned View
18001106 Pharmaceutical Composition Of Anti-Il-17a Antibodies And Use Thereof Abandoned View
18479371 Cardiac Troponin I Specific Antibody, Kit And Uses Thereof Patented View
18015690 Cd20 Binding Molecules And Uses Thereof Patented View
18355975 Methods Of Treating Gastrointestinal Immune-Related Adverse Events In Immune Oncology Treatments Patented View
18362625 Antibodies To Cd40 With Enhanced Agonist Activity Patented View
18247653 Caninized Antibodies To Canine Interleukin-31 Receptor Alpha Patented View
17965967 Means And Methods For Treating Angiogenesis-Related Diseases Patented View
18436312 Cd8a-Binding Fibronectin Type Iii Domains Patented View
17930548 Sparc Assay Patented View
17622507 Targeting Galectin-9 As A Therapeutic Strategy For T-Cell Exhaustion In T-Cell Acute Lymphoblastic Leukemia Patented View
17796796 Compositions And Methods For Treating Liver Disease Abandoned View
19222996 Methods For Treatment Using Anti-Alpha4beta7 Antibody Patented View
17585174 Anti-Alpha-Synuclein Antibodies Patented View
17627070 Anti-Trem-1 Antibodies And Uses Thereof Abandoned View
17527238 Serum Albumin-Binding Fibronectin Type Iii Domains Patented View
18354934 Cd1a Antibodies And Uses Thereof Patented View
17793026 Anti-Nkp30 Antibodies And Methods Of Use Abandoned View
18356305 Method Abandoned View
17746594 Treatment Of Neuroinflammatory Disease Abandoned View
17131946 Antibody Which Is Directed Against Galectin-9 And Is An Inhibitor Of The Suppressor Activity Of Regulatory T Lymphocytes Patented View
17774972 Molecule Capable Of Binding To Human 4-1bb And Its Application Thereof Abandoned View
18515723 Sh3yl1 Antibodies, Compositions Comprising The Same, And Vectors And Uses Thereof Patented View
17634430 Tetranectin-Targeting Monoclonal Antibodies To Fight Against Lethal Sepsis And Other Pathologies Patented View
17775727 Anti-Varicella-Zoster Virus Antibody Patented View
18533296 Anti-Sema3a Antibodies And Their Uses For Treating A Thrombotic Disease Of The Retina Abandoned View
18477254 Humanized And Chimeric Monoclonal Antibodies To Cd47 Abandoned View
18361780 Compositions And Methods For Disabling Myeloid Cells Expressing Trem1 Abandoned View
18384176 Inhibiting Anti-Enpp1 Antibodies Patented View
17582639 Treatment Of Diseases With Sequential Administration Of An Agent Capable Of Up-Regulating Cd73 And Glucocorticoids Patented View
18242215 Novel Anti-Angptl3 Antibodies Suitable For High Concentration Compositions And Subcutaneous Administration Abandoned View
18435158 Targeted Delivery Of Immunoregulatory Drugs Patented View
17800879 Anti-Dkk-1 Antibody Promoting Growth Of Human Dermal Papilla Cell And Use Thereof Patented View
17726144 Alpha-Synuclein Protofibril-Binding Antibodies Abandoned View
18507736 Peptides Patented View
17995168 Fully Human Anti-Human Cd22 Chimeric Antigen Receptor And Application Thereof Patented View
18739089 Compositions And Methods For Treating Severe Asthma Abandoned View
17859996 Methods For Treating Patients With Familial Hypercholesterolemia Abandoned View
16760379 Method For Treatment Of Cancer Abandoned View
17454837 Combination Therapies Using Anti-Pseudomonas Psl And Pcrv Binding Molecules Patented View
18815390 Fusion Protein Comprising Anti-Cd73 Antibody And Il-2, And Use Thereof Patented View
18394365 Treatment Of Cardiometabolic Disease With Inhibitors Of Type I Interferon Signalling Patented View
17823800 Compositions And Methods For Detecting And Regulating Fibronectin-Integrin Interaction And Signaling Patented View
17045372 Methods And Materials For Treating Graft-Versus-Host Disease Abandoned View
17615970 Antibody Capable Of Binding To Thymic Stromal Lymphopoietin And Use Thereof Patented View
18338297 Anti-Lag3 Antibodies Abandoned View
18349027 Anti-C1s Antibodies And Methods Of Use Thereof Patented View
17184116 Method Of Treating Primary Sclerosing Cholangitis Patented View
18338946 Anti-Par-2 Antibodies And Methods Of Use Thereof Patented View
18091145 Method For Detecting Or Treating Triple Negative Breast Cancer Patented View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.